Relationships Between Body Image and Body Parameters in Men Under Long-Term Fasting Conditions

Nutrients, Journal Year: 2025, Volume and Issue: 17(6), P. 1023 - 1023

Published: March 14, 2025

Background/Objectives: Fasting and physical exertion positively affect body mass composition. This study aimed to examine the effects of changes induced by eight days water-only fasting a test their influence on satisfaction image parameters in middle-aged men. Methods: Fifteen participants were assessed for (height, mass, composition) psychological (body satisfaction, evaluation parts, determinants) aspects before after intervention, both at rest post-exercise. Correlation concordance coefficients calculated analyzed variables. Results: It was found that intervention led reduction favorable shift composition, while also increasing with one’s its specific parts. impacted volunteers’ self-assessment health status. Selected remained an average level male population did not change following fasting. Attitudes toward weight control methods perceived effectiveness either. Participants favored reducing food intake eliminating high-calorie products from diet, rejecting use pathological typically associated eating disorders. A few associations between corporeality observed, whereas significant correlations parts positive confirmed. Conclusions: The above suggest conditions resulting lead components but do alter image.

Language: Английский

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review

Obesities, Journal Year: 2025, Volume and Issue: 5(2), P. 26 - 26

Published: April 18, 2025

Obesity represents a global health challenge, with critical and urgent need for long-term, sustainable management strategies. Tirzepatide is novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist. At first approved the treatment of type 2 diabetes mellitus, tirzepatide one latest clinically commercially available pharmacological options obesity management. This narrative review aimed to synthesize existing clinical evidence on efficacy safety in non-diabetic obese individuals. A comprehensive literature search was conducted using PubMed, Scopus, Web Science, ClinicalTrials.gov, Google Scholar databases identify relevant trials, meta-analyses, original studies assessing weight-loss impact from 2022 onwards. Synthesized indicated that achieved up 20.9% weight loss over 72 weeks (SURMOUNT-1), 18.4% after lifestyle intervention (SURMOUNT-3), 17.5% Chinese adults (SURMOUNT-CN), 25.3% continued 88 (SURMOUNT-4). Meta-analyses confirmed higher odds ≥5–20% versus semaglutide liraglutide, significantly reducing body mass index, waist circumference, blood pressure, atherosclerotic cardiovascular disease risk. Health-related quality life improved greater loss, gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild moderate, <5% discontinuation. significant cardiometabolic benefits, individuals, further research needed long-term efficacy, safety, application.

Language: Английский